ALX Oncology Holdings Inc (ALXO)
1.37
+0.08
(+6.20%)
USD |
NASDAQ |
Nov 22, 11:05
ALX Oncology Holdings Total Liabilities (Quarterly): 48.91M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 48.91M |
| June 30, 2024 | 55.30M |
| March 31, 2024 | 48.46M |
| December 31, 2023 | 52.84M |
| September 30, 2023 | 51.36M |
| June 30, 2023 | 33.24M |
| March 31, 2023 | 37.75M |
| December 31, 2022 | 43.02M |
| September 30, 2022 | 30.73M |
| June 30, 2022 | 29.70M |
| Date | Value |
|---|---|
| March 31, 2022 | 20.08M |
| December 31, 2021 | 17.13M |
| September 30, 2021 | 14.56M |
| June 30, 2021 | 16.28M |
| March 31, 2021 | 14.43M |
| December 31, 2020 | 6.209M |
| September 30, 2020 | 10.43M |
| June 30, 2020 | 12.47M |
| March 31, 2020 | 9.282M |
| December 31, 2019 | 10.95M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
6.209M
Minimum
Dec 2020
55.30M
Maximum
Jun 2024
28.16M
Average
24.89M
Median
Total Liabilities (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 1.438B |
| Neurocrine Biosciences Inc | 816.10M |
| Eton Pharmaceuticals Inc | 19.86M |
| Verve Therapeutics Inc | 155.36M |
| Immuneering Corp | 10.84M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 185.72M |
| Shareholders Equity (Quarterly) | 136.81M |